Company / Financials
TENAX THERAPEUTICS, INC. Financials
FY2012-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$0
FY2025
Net Income
-$17.6M
FY2025 · -128.3% YoY
Profit Margin
-
FY2025 · net income / revenue
ROE
-19.1%
FY2025 · return on equity
Total Assets
$104.2M
FY2025
Total Debt
-
FY2025
Equity
$92.0M
FY2025
ROA
-16.9%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.24 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$0Net Income HistoryProfit after all expenses and taxes-$17.6M-128.3% YoYGross Profit HistoryRevenue minus cost of goods sold-Cost of Revenue HistoryDirect costs of producing goods and services sold-Operating Income HistoryProfit from core business operations before interest and taxes-$19.5M-136.8% YoYSG&A Expense HistorySelling, general, and administrative expenses$6.8M+35.6% YoYR&D Expense HistoryResearch and development spending$12.7M+293.6% YoYInterest Expense HistoryCost of borrowing and debt obligations$23.0K-4.2% YoYIncome Tax HistoryTotal income tax expense$0EPS (Basic) HistoryBasic earnings per share-$1.15+96.3% YoY